- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cost Drivers in Lupus Nephritis
Panelists discuss the main cost drivers of lupus nephritis treatment, comparing direct medical costs to those of other chronic conditions and examining indirect costs such as lost productivity and disability.
Video Player is loading.
EP: 1.Understanding the Clinical Burden and Prevalence of Lupus Nephritis
Now Viewing
EP: 2.Cost Drivers in Lupus Nephritis
EP: 3.Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies
EP: 4.Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making
EP: 5.Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches
EP: 6.Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis
EP: 7.Improving Access to Lupus Nephritis Treatment: Strategies and Resources
EP: 8.Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results
EP: 9.Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis
EP: 10.From Guidelines to Practice: Advancing Lupus Nephritis Treatment
EP: 11.Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice
- What are the main cost drivers associated with the treatment and management of lupus nephritis?
- How do direct medical costs for lupus nephritis compare with other chronic conditions?
- What are some of the indirect costs (eg, lost productivity, disability) associated with lupus nephritis?
Related Videos
Building Better Collaboration: Reducing Care Delays in Managing mCRC
Best Practices for Overcoming mCRC Prior Authorization Barriers
Introduction to IgA Nephropathy
Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies
CGM Coverage and Access
Minimizing Antibiotic Resistance Development in Uncomplicated UTIs
Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas
Related Content
